JMP Securities analyst Constantine Davides raised the firm’s price target on Option Care Health (OPCH) to $35 from $30 and keeps an Outperform rating on the shares amid a broader research note on Healthcare Services. The firm believes a higher multiple is justified given the elimination of the Stelara overhang and a lack of any meaningful single-product risk ex-Stelara.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health upgraded to Buy from Hold at Jefferies
- Option Care Health price target raised to $33 from $32 at Barrington
- BofA upgrades Option Care Health to Buy on earnings visibility
- Option Care Health upgraded to Buy from Neutral at BofA
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz